Your browser doesn't support javascript.
Immunogenicity to COVID-19 mRNA vaccine third dose in people living with HIV.
Vergori, Alessandra; Cozzi Lepri, Alessandro; Cicalini, Stefania; Matusali, Giulia; Bordoni, Veronica; Lanini, Simone; Meschi, Silvia; Iannazzo, Roberta; Mazzotta, Valentina; Colavita, Francesca; Mastrorosa, Ilaria; Cimini, Eleonora; Mariotti, Davide; De Pascale, Lydia; Marani, Alessandra; Gallì, Paola; Garbuglia, AnnaRosa; Castilletti, Concetta; Puro, Vincenzo; Agrati, Chiara; Girardi, Enrico; Vaia, Francesco; Antinori, Andrea.
  • Vergori A; HIV/AIDS Unit, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Rome, Italy. alessandra.vergori@inmi.it.
  • Cozzi Lepri A; Centre for Clinical Research, Epidemiology, Modelling and Evaluation (CREME), Institute for Global Health, UCL, London, UK.
  • Cicalini S; HIV/AIDS Unit, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Rome, Italy.
  • Matusali G; Laboratory of Virology, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Rome, Italy.
  • Bordoni V; Laboratory of Cellular Immunology and Clinical Pharmacology, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Roma, Italy.
  • Lanini S; HIV/AIDS Unit, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Rome, Italy.
  • Meschi S; Laboratory of Virology, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Rome, Italy.
  • Iannazzo R; HIV/AIDS Unit, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Rome, Italy.
  • Mazzotta V; HIV/AIDS Unit, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Rome, Italy.
  • Colavita F; Laboratory of Virology, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Rome, Italy.
  • Mastrorosa I; HIV/AIDS Unit, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Rome, Italy.
  • Cimini E; Laboratory of Cellular Immunology and Clinical Pharmacology, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Roma, Italy.
  • Mariotti D; Laboratory of Cellular Immunology and Clinical Pharmacology, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Roma, Italy.
  • De Pascale L; HIV/AIDS Unit, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Rome, Italy.
  • Marani A; Health Direction, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Roma, Italy.
  • Gallì P; Health Direction, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Roma, Italy.
  • Garbuglia A; Laboratory of Virology, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Rome, Italy.
  • Castilletti C; Laboratory of Virology, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Rome, Italy.
  • Puro V; Risk Management Unit, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Roma, Italy.
  • Agrati C; Laboratory of Cellular Immunology and Clinical Pharmacology, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Roma, Italy.
  • Girardi E; Scientific Direction, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Roma, Italy.
  • Vaia F; Health Direction, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Roma, Italy.
  • Antinori A; HIV/AIDS Unit, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Rome, Italy.
Nat Commun ; 13(1): 4922, 2022 08 22.
Article in English | MEDLINE | ID: covidwho-2000884
ABSTRACT
In order to investigate safety and immunogenicity of SARS-CoV-2 vaccine third dose in people living with HIV (PLWH), we analyze anti-RBD, microneutralization assay and IFN-γ production in 216 PLWH on ART with advanced disease (CD4 count <200 cell/mm3 and/or previous AIDS) receiving the third dose of a mRNA vaccine (BNT162b2 or mRNA-1273) after a median of 142 days from the second dose. Median age is 54 years, median CD4 nadir 45 cell/mm3 (20-122), 93% HIV-RNA < 50 c/mL. In 68% of PLWH at least one side-effect, generally mild, is recorded. Humoral response after the third dose was strong and higher than that achieved with the second dose (>2 log2 difference), especially when a heterologous combination with mRNA-1273 as third shot is used. In contrast, cell-mediated immunity remain stable. Our data support usefulness of third dose in PLWH currently receiving suppressive ART who presented with severe immune dysregulation.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: HIV Infections / Immunogenicity, Vaccine / COVID-19 Vaccines / COVID-19 Topics: Vaccines Limits: Humans / Middle aged Language: English Journal: Nat Commun Journal subject: Biology / Science Year: 2022 Document Type: Article Affiliation country: S41467-022-32263-7

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: HIV Infections / Immunogenicity, Vaccine / COVID-19 Vaccines / COVID-19 Topics: Vaccines Limits: Humans / Middle aged Language: English Journal: Nat Commun Journal subject: Biology / Science Year: 2022 Document Type: Article Affiliation country: S41467-022-32263-7